

DAFTAR PUSTAKA

- Agostini, J.V., Leo-Summers, L.S. and Inouye, S.K. (2001) 'Cognitive and Other Adverse Effects of Diphenhydramine Use in Hospitalized Older Patients', *Archives of Internal Medicine*, 161(17), pp. 2091–2097. Available at: <https://doi.org/10.1001/archinte.161.17.2091>.
- Aiyer, A.N. *et al.* (2007) 'Predictors of Significant Short-Term Increases in Blood Pressure in a Community-Based Population', *The American Journal of Medicine*, 120(11), pp. 960–967. Available at: <https://doi.org/10.1016/j.amjmed.2007.06.021>.
- Altamura, A.C. *et al.* (2015) 'Integrated treatment of schizophrenia', *Journal of Psychopathology*, 21, pp. 168–193.
- American Psychiatric Association (ed.) (2013) *Diagnostic and statistical manual of mental disorders: DSM-V*. 5th edn. Washington, DC.
- Anagnostakis, K. and Dex, G. (2010) 'P03-316 - Gender differences in the extrapyramidal side effects of antipsychotic medication', *European Psychiatry*, 25, p. 931. Available at: [https://doi.org/10.1016/S0924-9338\(10\)70922-6](https://doi.org/10.1016/S0924-9338(10)70922-6).
- Apriliya, T.N. and Puspitasari, I.M. (2022) 'Review Artikel : Adverse Drug Events Aripiprazole Pada Pasien Dengan Gejala Psikosis', *Farmaka*, 21(1).
- Balhara, Y. and Verma, R. (2012) 'Schizophrenia and Suicide', 22.
- Bernardo, M. *et al.* (2011) 'Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry', *Revista de Psiquiatría y Salud Mental*, 4(3), pp. 150–168. Available at: <https://doi.org/10.1016/j.rpsm.2011.07.003>.
- Brand, B.A., de Boer, J.N. and Sommer, I.E.C. (2021) 'Estrogens in schizophrenia: progress, current challenges and opportunities', *Current Opinion in Psychiatry*, 34(3), pp. 228–237. Available at: <https://doi.org/10.1097/YCO.0000000000000699>.
- Bruins, J. *et al.* (2017) 'Persistent Low Rates of Treatment of Metabolic Risk Factors in People With Psychotic Disorders: A PHAMOUS Study', *The Journal of Clinical Psychiatry*, 78(8), pp. 1117–1125. Available at: <https://doi.org/10.4088/JCP.16m10831>.
- Buckley, P.F. (2007) 'Receptor-Binding Profiles of Antipsychotics: Clinical Strategies When Switching Between Agents', *J Clin Psychiatry*, 68 (6), pp. 5–9.

- Carli, M. *et al.* (2021) 'Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences', *Pharmaceuticals*, 14(3), p. 238. Available at: <https://doi.org/10.3390/ph14030238>.
- Carlsson, A. (2002) 'The Dopamine Hypothesis of Schizophrenia: New Aspects', *Catecholamine Research*. Edited by T. Nagatsu *et al.*, 53, pp. 417–422. Available at: https://doi.org/10.1007/978-1-4757-3538-3_100.
- Casey, A.B. and Canal, C.E. (2017) 'Classics in Chemical Neuroscience: Aripiprazole', *ACS Chemical Neuroscience*, 8(6), pp. 1135–1146. Available at: <https://doi.org/10.1021/acscchemneuro.7b00087>.
- Chan, V. (2017) 'Schizophrenia and Psychosis', *Child and Adolescent Psychiatric Clinics of North America*, 26(2), pp. 341–366. Available at: <https://doi.org/10.1016/j.chc.2016.12.014>.
- Charlson, F.J. *et al.* (2018) 'Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016', *Schizophrenia Bulletin*, 44(6), pp. 1195–1203. Available at: <https://doi.org/10.1093/schbul/sby058>.
- Chrzanowski, W.K. *et al.* (2006) 'Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine', *Psychopharmacology*, 189(2), pp. 259–266. Available at: <https://doi.org/10.1007/s00213-006-0564-3>.
- Correll, C.U. *et al.* (2009) 'Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials', *Schizophrenia Bulletin*, 35(2), pp. 443–457. Available at: <https://doi.org/10.1093/schbul/sbn018>.
- Dania, H. *et al.* (2019) 'Effect of Atypical Antipsychotic on Blood Pressure in Inpatients with Schizophrenia of Prof. Dr. Soerojo Mental Health Hospital Magelang', *Journal of Pharmacy and Bioallied Sciences*, 11(Suppl 4), p. S580. Available at: https://doi.org/10.4103/jpbs.JPBS_211_19.
- Davidson, M. and Carpenter, W.T. (2024) 'Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence', *Schizophrenia Bulletin*, 50(1), pp. 14–21. Available at: <https://doi.org/10.1093/schbul/sbad145>.
- Dayabandara, M. *et al.* (2017) 'Antipsychotic-associated weight gain: management strategies and impact on treatment adherence', *Neuropsychiatric Disease and Treatment*, 13, pp. 2231–2241. Available at: <https://doi.org/10.2147/NDT.S113099>.

De Hert, M. *et al.* (2009) 'Metabolic syndrome in people with schizophrenia: a review', *World Psychiatry*, 8(1), pp. 15–22. Available at: <https://doi.org/10.1002/j.2051-5545.2009.tb00199.x>.

DiPiro, J.T. (ed.) (2020) *Pharmacotherapy: a pathophysiologic approach*. Eleventh edition. New York: McGraw Hill Medical.

Divac, N. *et al.* (2014) 'Second-Generation Antipsychotics and Extrapyramidal Adverse Effects', *BioMed Research International*, 2014, pp. 1–6. Available at: <https://doi.org/10.1155/2014/656370>.

Drugbank (2023) 'Aripiprazole'. Drugbank Online. Available at: <https://go.drugbank.com/drugs/DB01238>.

D'Souza, R.S. and Hooten, W.M. (2023) 'Extrapyramidal Symptoms', in *StatPearls [Internet]*. StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK534115/> (Accessed: 17 October 2024).

Ezequiel, U. (2016) 'Neuropsychological subtypes of schizophrenia and prefrontal circuits'.

Farah, A. (2005) 'Atypicality of Atypical Antipsychotics', *J Clin Psychiatry*, 7(6). Available at: <https://doi.org/10.4088/PCC.v07n0602>.

Gettu, N. and Abdolreza, S. (2022) *Aripiprazole*. StatPearls Publishing.

Girgis, R.R., Merrill, D.B., Vorel, S.R., Kim, E., *et al.* (2011) 'ARIPIPRAZOLE VERSUS HALOPERIDOL TREATMENT IN EARLY-STAGE SCHIZOPHRENIA', *Journal of psychiatric research*, 45(6), pp. 756–762. Available at: <https://doi.org/10.1016/j.jpsychires.2010.09.003>.

Girgis, R.R., Merrill, D.B., Vorel, S.R., Edward Kim, *et al.* (2011) 'Aripiprazole versus haloperidol treatment in early-stage schizophrenia', *Journal of Psychiatric Research*, 45(6), pp. 756–762. Available at: <https://doi.org/10.1016/j.jpsychires.2010.09.003>.

Gogtay, N. *et al.* (2011) 'Age of Onset of Schizophrenia: Perspectives From Structural Neuroimaging Studies', *Schizophrenia Bulletin*, 37(3), pp. 504–513. Available at: <https://doi.org/10.1093/schbul/sbr030>.

Gómez-Revuelta, M. *et al.* (2020) 'Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone', *International Journal of Neuropsychopharmacology*, 23(4), pp. 217–229. Available at: <https://doi.org/10.1093/ijnp/pyaa004>.

- Hakami, A.Y. *et al.* (2022) 'The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study', *Frontiers in Psychiatry*, 13, p. 914165. Available at: <https://doi.org/10.3389/fpsy.2022.914165>.
- Hartanti, M.D. and Saleh, I. (2022) 'Aspek Farmakogenomik Pada Polimorfisme Gen C957T Pasien Skizofrenia Dengan Terapi Aripiprazole', 18(1).
- Hwang, T.-J. *et al.* (2015) 'Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics', *Journal of Clinical Psychopharmacology*, 35(6), pp. 635–644. Available at: <https://doi.org/10.1097/JCP.0000000000000426>.
- Immonen, J. *et al.* (2017) 'Age at onset and the outcomes of schizophrenia: A systematic review and meta-analysis: Age at onset and the outcomes of schizophrenia', *Early Intervention in Psychiatry*, 11(6), pp. 453–460. Available at: <https://doi.org/10.1111/eip.12412>.
- Irma, F. (2012) *Penentuan Validitas dan Realibilitas Instrumen Prince Henry Hospital Akathisia Rating Scale Versi Bahasa Indonesia*. Universitas Indonesia.
- Jen, Y.-W. *et al.* (2020) 'Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?', *BMC Psychiatry*, 20(1), p. 552. Available at: <https://doi.org/10.1186/s12888-020-02957-7>.
- Jilani, T.N. *et al.* (2024) 'Trihexyphenidyl', in *StatPearls [Internet]*. StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK519488/> (Accessed: 15 October 2024).
- Kamijima, K. *et al.* (2013) 'Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study)', *Journal of Affective Disorders*, 151(3), pp. 899–905. Available at: <https://doi.org/10.1016/j.jad.2013.07.035>.
- Kanahara, N. *et al.* (2020) 'The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study', *International Clinical Psychopharmacology*, 35(6), pp. 338–344. Available at: <https://doi.org/10.1097/YIC.0000000000000322>.
- Keks, N., Schwartz, D. and Hope, J. (2019) 'Stopping and switching antipsychotic drugs', *Australian Prescriber*, 42(5), p. 152. Available at: <https://doi.org/10.18773/austprescr.2019.052>.

Kementerian Kesehatan RI (2018) *Laporan Nasional Riskesdas*. Kementerian Kesehatan Republik Indonesia, pp. 223–225.

Kementerian Kesehatan RI (2021) ‘Pedoman Pelayanan Kefarmasian Untuk Pasien Gangguan Jiwa’. Kementerian Kesehatan Republik Indonesia.

Kementrian Kesehatan RI (2015) ‘Keputusan Menteri Kesehatan RI Nomor HK 02.02/MENKES/73/2015 Tentang Pedoman Nasional Kedokteran Jiwa’, in. Jakarta: Kementerian Kesehatan Republik Indonesia.

Khalil, H. and Zeltser, R. (2023) ‘Antihypertensive Medications’, in *StatPearls [Internet]*. StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK554579/> (Accessed: 9 December 2024).

Kim, S. *et al.* (2023) ‘Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse’, *Clinical Psychopharmacology and Neuroscience*, 21(4), pp. 769–777. Available at: <https://doi.org/10.9758/cpn.23.1057>.

Kragelund, C. *et al.* (2007) ‘Metabolic Syndrome and Mortality in Stable Coronary Heart Disease: Relation to Gender’, *International Journal of Cardiology*, 121(1), pp. 62–67. Available at: <https://doi.org/10.1016/j.ijcard.2007.04.068>.

Kumar P.B, S. *et al.* (2017) ‘A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia’, *Current Neuropharmacology*, 15(8), pp. 1073–1084. Available at: <https://doi.org/10.2174/1570159X15666170113100611>.

Lally, J. and MacCabe, J.H. (2015) ‘Antipsychotic medication in schizophrenia: a review’, *British Medical Bulletin*, 114(1), pp. 169–179. Available at: <https://doi.org/10.1093/bmb/ldv017>.

Lerner, V. *et al.* (2004) ‘Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder’, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 28(1), pp. 89–98. Available at: <https://doi.org/10.1016/j.pnpbp.2003.09.024>.

Letmaier, M. *et al.* (2006) ‘Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting’, *The International Journal of Neuropsychopharmacology*, 9(05), p. 529. Available at: <https://doi.org/10.1017/S1461145705006073>.

Leucht, S. *et al.* (2023) ‘Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-

- analysis', *World Psychiatry*, 22(2), pp. 315–324. Available at: <https://doi.org/10.1002/wps.21089>.
- Liu, J. and Fu, L. (2022) 'Metabolic syndrome in patients with schizophrenia: Why should we care', *Medicine*, 101(32), p. e29775. Available at: <https://doi.org/10.1097/MD.00000000000029775>.
- Marder, S.R. *et al.* (2003) 'Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials', *Schizophrenia Research*, 61(2–3), pp. 123–136. Available at: [https://doi.org/10.1016/S0920-9964\(03\)00050-1](https://doi.org/10.1016/S0920-9964(03)00050-1).
- Masand, P.S. (2000) 'Side Effects of Antipsychotics in the Elderly', *J Clin Psychiatry*, 61(suppl 8), pp. 43–49.
- Massie, J. and Lewis, S. (1999) 'Duration of treatment in schizophrenia', *The Journal of Forensic Psychiatry*, 10(3), pp. 491–496. Available at: <https://doi.org/10.1080/09585189908402153>.
- Meltzer, H.Y. *et al.* (2012) 'Pimavanserin, a selective serotonin (5-HT)_{2A}-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day', *Schizophrenia Research*, 141(2), pp. 144–152. Available at: <https://doi.org/10.1016/j.schres.2012.07.029>.
- Mitchell, A.J. *et al.* (2013) 'Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis', *Schizophrenia Bulletin*, 39(2), pp. 306–318. Available at: <https://doi.org/10.1093/schbul/sbr148>.
- Mohr, P., Masopust, J. and Kopeček, M. (2022) 'Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?', *Frontiers in Psychiatry*, 12, p. 781946. Available at: <https://doi.org/10.3389/fpsy.2021.781946>.
- Muench, J. and M. Hamer, A. (2010) 'American Family Physician', 81(5).
- Musdalifah, W., Susanti, R. and Robiyanto, R. (2020) 'Evaluasi Penggunaan Obat Triheksifenidil sebagai Terapi Adjuvan pada Pasien Skizofrenia di Instalasi Rawat Inap di Rumah Sakit Jiwa Daerah Sungai Bangkong Pontianak', *Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN* [Preprint].
- Nyhuis, A.W. *et al.* (2010) 'Predictors of switching antipsychotic medications in the treatment of schizophrenia', *BMC Psychiatry*, 10, p. 75. Available at: <https://doi.org/10.1186/1471-244X-10-75>.

- Obermeier, M. *et al.* (2011) 'Is the PANSS used Correctly? A Systematic Review', *BMC Psychiatry*, 11(1), p. 113. Available at: <https://doi.org/10.1186/1471-244X-11-113>.
- Otsuka Pharmaceutical (2014) 'Full Prescribing Information: Abilify (Aripiprazole)'. Otsuka American Pharmaceutical, Inc.
- Owen, M.J., Sawa, A. and Mortensen, P.B. (2016) 'Schizophrenia', *The Lancet*, 388(10039), pp. 86–97. Available at: [https://doi.org/10.1016/S0140-6736\(15\)01121-6](https://doi.org/10.1016/S0140-6736(15)01121-6).
- Pagsberg, A.K. *et al.* (2017) 'Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial', *The Lancet Psychiatry*, 4(8), pp. 605–618. Available at: [https://doi.org/10.1016/S2215-0366\(17\)30166-9](https://doi.org/10.1016/S2215-0366(17)30166-9).
- Pani, L., Pira, L. and Marchese, G. (2007) 'Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy', *European Psychiatry*, 22(5), pp. 267–275. Available at: <https://doi.org/10.1016/j.eurpsy.2007.02.005>.
- Parks, K.A. *et al.* (2018) 'Acute Blood Pressure Changes Associated With Antipsychotic Administration to Psychiatric Inpatients', *The Primary Care Companion for CNS Disorders*, 20(4), p. 26587. Available at: <https://doi.org/10.4088/PCC.18m02299>.
- Patel, K.R. *et al.* (2014) 'Schizophrenia: Overview and Treatment Options', *Pharmacy and Therapeutics*, 39(9), pp. 638–645.
- PDSKJI (2011) 'Konsensus Penatalaksanaan Gangguan Skizofrenia'. Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia.
- Piras, M. *et al.* (2024) 'Aripiprazole dose associations with metabolic adverse effect : Results from a longitudinal study', *Schizophrenia Research*, 270, pp. 403–409. Available at: <https://doi.org/10.1016/j.schres.2024.07.007>.
- Purwandityo, A.G. *et al.* (2018) 'Pengaruh Antipsikotik terhadap Penurunan Skor The Positive and Negative Syndrome Scale-Excited Component', *Indonesian Journal of Clinical Pharmacy*, 7(1), pp. 19–29. Available at: <https://doi.org/10.15416/ijcp.2018.7.1.19>.
- Qian, L. *et al.* (2021) 'Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials', Volume 12. Available at:

<https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.717715/full> (Accessed: 22 October 2024).

Rahaya, A. and Cahaya, N. (2016) 'Studi Retrospektif Penggunaan Trihexyfenidil pada Pasien Skizofrenia Rawat Inap yang Mendapat Terapi Antipsikotik di Rumah Sakit Jiwa Sambang Lihum', *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)*, 2(2), pp. 124–131. Available at: <https://doi.org/10.22487/j24428744.2016.v2.i2.5986>.

Ramsi, R.K. and Zulaikha, A. (2022) 'Patofisiologi dan Tatalaksana Sindrom Ekstrapiramidal', *AVERROUS: Jurnal Kedokteran dan Kesehatan Malikussaleh*, 8(2), p. 64. Available at: <https://doi.org/10.29103/averrous.v8i2.8770>.

Riawan, H. (2020) *Perbandingan Pengaruh Regimen Terapi Antipsikotik Berbasis Risperidon terhadap Status Sindrom Ekstrapiramidal, Fungsi Kognitif, & Gangguan Metabolik pada Pasien Schizophrenia di RS Ernaldi Bahar Palembang*. Universitas Gadjah Mada.

Saharuddin (2020) *Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr. Ernaldi Bahar Palembang*. Universitas Gadjah Mada.

Schultz, S.H., North, S.W. and Shields, C.G. (2007) 'Schizophrenia : A Review', *American Academy of Family Physicians* [Preprint].

Seeman, M.V. (2004) 'Gender Differences in the Prescribing of Antipsychotic Drugs', *American Journal of Psychiatry*, 161(8), pp. 1324–1333. Available at: <https://doi.org/10.1176/appi.ajp.161.8.1324>.

Seeman, M.V. (2021) 'The Pharmacodynamics of Antipsychotic Drugs in Women and Men', *Frontiers in Psychiatry*, 12, p. 650904. Available at: <https://doi.org/10.3389/fpsyt.2021.650904>.

Sicari, V. and Zabbo, C.P. (2023) 'Diphenhydramine', in *StatPearls [Internet]*. StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK526010/> (Accessed: 15 October 2024).

Sobiś, J. *et al.* (2015) 'Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity', *Pharmacological Reports*, 67(2), pp. 353–359. Available at: <https://doi.org/10.1016/j.pharep.2014.09.007>.

Sommer, I.E. *et al.* (2014) 'Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update', *Schizophrenia*

Bulletin, 40(1), pp. 181–191. Available at:
<https://doi.org/10.1093/schbul/sbt139>.

Stepnicki, P., Kondej, M. and Kaczor, A.A. (2018) ‘Current Concepts and Treatments of Schizophrenia’, *Molecules*, 23(8), p. 2087. Available at: <https://doi.org/10.3390/molecules23082087>.

Stip, E. and Tourjman, V. (2010) ‘Aripiprazole in schizophrenia and schizoaffective disorder: A review’, *Clinical Therapeutics*, 32, pp. S3–S20. Available at: <https://doi.org/10.1016/j.clinthera.2010.01.021>.

Stogios, N. *et al.* (2023) ‘Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations’, *Current Psychiatry Reports*, 25(11), pp. 707–721. Available at: <https://doi.org/10.1007/s11920-023-01458-0>.

Stroup, T.S. and Gray, N. (2018) ‘Management of common adverse effects of antipsychotic medications’, *World Psychiatry*, 17(3), pp. 341–356. Available at: <https://doi.org/10.1002/wps.20567>.

Sudarshan, Y. and Cheung, B.M.Y. (2023) ‘Hypertension and psychosis’, *Postgraduate Medical Journal*, 99(1171), pp. 411–415. Available at: <https://doi.org/10.1136/postgradmedj-2021-141386>.

Thomas, P. *et al.* (2010) ‘Differences among Men and Women with Schizophrenia: A Study of US and Indian Samples’, *Psychiatry Investigation*, 7(1), p. 9. Available at: <https://doi.org/10.4306/pi.2010.7.1.9>.

Vanegas-Arroyave, N. *et al.* (2024) ‘An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders’, *CNS Drugs*, 38(4), pp. 239–254. Available at: <https://doi.org/10.1007/s40263-024-01078-z>.

Weiden, P.J. *et al.* (2019) ‘Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period’, *CNS Spectrums*, 24(4), pp. 419–425. Available at: <https://doi.org/10.1017/S1092852918000986>.

WHO (2022) ‘Schizophrenia’. Available at: <https://www.who.int/news-room/fact-sheets/detail/schizophrenia>.

Yasui-Furukori, N. *et al.* (2012) ‘Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients’, *Journal of Psychopharmacology*, 26(6), pp. 806–812. Available at: <https://doi.org/10.1177/0269881111405555>.

- Yoon, H.W. *et al.* (2016) ‘Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study’, *Clinical Neuropharmacology*, 39(6), pp. 288–294. Available at: <https://doi.org/10.1097/WNF.0000000000000175>.
- Yulianti, Y. (2015) ‘Cetak Biru Pelayanan Pasien di Rumah Sakit Jiwa Provinsi Jawa Barat Tahun 2014’. *Jurnal Administrasi Kebijakan Kesehatan*.
- Zeller, S. *et al.* (2017) ‘Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses’, *BJPsych Open*, 3(6), pp. 285–290. Available at: <https://doi.org/10.1192/bjpo.bp.117.005363>.
- Zhan, N. *et al.* (2023) ‘The genetic basis of onset age in schizophrenia: evidence and models’, *Frontiers in Genetics*, 14, p. 1163361. Available at: <https://doi.org/10.3389/fgene.2023.1163361>.